Positioned to transform the HBV treatment landscape and address the HBV global market opportunity

Learn How >

Portfolio of assets combining multiple technologies aimed at curing HBV

Learn How >

Proven scientific leadership in antiviral and RNAi drug discovery and development

Learn How >

About Arbutus Biopharma

Arbutus Biopharma Corporation is a publicly-traded (NASDAQ: ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for people with chronic hepatitis B virus ("HBV") infection. We are advancing multiple drug product candidates that may be combined into a potentially curative regimen for chronic HBV infection. Arbutus has also initiated a drug discovery and development effort for treating coronaviruses (including COVID-19). 


Read More



Recent News

View all news